Cell Therapy Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy Type (Autologous, Allogenic), By Therapeutic Area (Oncology, Cardiovascular Diseases, Musculoskeletal Disorders, Dermatology), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 6.74 Billion
CAGR (2026-2031)	12.02%
Fastest Growing Segment	Oncology
Largest Market	North America
Market Size (2031)	USD 13.32 Billion

Market Overview

The Global Cell Therapy Market will grow from USD 6.74 Billion in 2025 to USD 13.32 Billion by 2031 at a 12.02% CAGR. Cell therapy involves the administration of viable cells into a patient to repair or replace damaged tissues for the treatment of various diseases. The market is primarily driven by the rising prevalence of chronic conditions such as cancer and autoimmune disorders which necessitates the development of effective therapeutic interventions. Additionally, continuous improvements in bioprocessing and gene editing capabilities have accelerated the clinical translation of these treatments. According to the 'American Society of Gene & Cell Therapy', in '2025', the global pipeline remained robust with more than 3,200 trials underway worldwide.

However, the high cost associated with manufacturing and treatment poses a significant challenge to market expansion. The complex logistics required for producing personalized therapies often result in elevated prices that strain healthcare budgets and restrict patient access. Consequently, securing adequate reimbursement from insurance payers remains a critical hurdle that could impede the widespread commercial adoption of these therapies.

Key Market Drivers

The rising global prevalence of chronic and oncological disorders acts as the primary catalyst for the cell therapy market, creating an urgent demand for curative treatments like CAR-T and TCR therapies. As the incidence of complex diseases surges, healthcare systems are increasingly moving beyond symptom management toward advanced cellular medicines to address conditions refractory to conventional biologics. This shift is particularly acute in oncology, where the growing patient burden necessitates the scalable adoption of these life-saving interventions. According to the American Cancer Society, January 2025, in the 'Cancer Facts & Figures 2025', a projected 2,041,910 new cancer cases are expected to occur in the United States, underscoring the critical necessity for novel therapeutic modalities to address this escalating health crisis.

Simultaneously, the market is propelled by an expanding pipeline of clinical trials and expedited regulatory approvals, which are diversifying the scope of cell therapies beyond hematological malignancies into solid tumors and autoimmune diseases. This innovation is supported by robust developmental activity and favorable regulatory designations that accelerate time-to-market for breakthrough assets. According to the American Society of Gene & Cell Therapy, October 2024, in the 'Q3 2024 Gene, Cell, + RNA Therapy Landscape Report', 51% of newly initiated gene therapy trials in the third quarter of 2024 targeted non-oncology indications, highlighting the broadening therapeutic application of these technologies. The overall scale of development further reinforces this growth trajectory. According to InGeNA, December 2024, in the 'Global Gene, Cell, and RNA Therapy Trends – Q3 2024 Update', the global therapy pipeline has matured significantly, now encompassing over 4,000 distinct treatments aimed at addressing a wide spectrum of unmet medical needs.

Download Free Sample Report

Key Market Challenges

The substantial costs associated with manufacturing and treatment act as a primary restraint on the commercial scalability of the global cell therapy market. Producing these personalized therapies requires intricate, labor-intensive logistical chains that elevate the cost of goods sold far beyond that of conventional medicines. These operational expenses are inevitably passed on to the healthcare system, creating a friction point where insurance payers often delay or limit coverage to protect their budgets. Consequently, even clinically successful therapies struggle to gain rapid market entry, as reimbursement negotiations become protracted and restrict patient eligibility to only the most severe cases.

This economic bottleneck directly impedes the broader market by concentrating financial success in a limited number of established treatments rather than allowing the wider pipeline to flourish. When access is restricted due to pricing pressures, the volume of treated patients remains low, preventing the economies of scale that could otherwise reduce future production costs. According to the 'Alliance for Regenerative Medicine', in '2025', global revenue distribution remained highly concentrated, with approximately 75 percent of the sector's total revenue generated by fewer than 10 commercial products. This disparity illustrates how market access barriers effectively stall the growth potential of the wider cell therapy landscape.

Key Market Trends

The emergence of allogeneic "off-the-shelf" therapy platforms is rapidly reshaping the market by addressing the logistical and financial limitations of autologous treatments. Unlike patient-specific therapies that require complex, time-consuming apheresis and individual processing, allogeneic candidates utilize healthy donor cells to create scalable batches available for immediate administration. This shift not only reduces manufacturing costs but also significantly shortens the vein-to-vein time, a critical factor for patients with rapidly progressing disease. The clinical viability of this approach is increasingly evident in solid tumor applications, which have historically proven difficult for cellular medicines. According to Allogene Therapeutics, November 2024, in the 'Third Quarter 2024 Financial Results', the Phase 1 TRAVERSE trial for ALLO-316 demonstrated an overall response rate of 50% in patients with CD70-positive renal cell carcinoma, validating the potential of allogeneic platforms to deliver potent efficacy outside of hematological malignancies.

Simultaneously, the widespread adoption of automated and closed-system manufacturing technologies is becoming a standard operational strategy to overcome production bottlenecks. Biopharmaceutical developers are transitioning away from manual, open-process techniques that are labor-intensive and prone to contamination, favoring fully automated platforms that ensure consistent product quality and higher throughput. This technological evolution is essential for meeting commercial demand and reducing the cost of goods sold, thereby facilitating broader market access. The industry's commitment to this transition is exemplified by major capital allocations toward advanced production infrastructure. According to Bristol Myers Squibb, April 2024, in the 'Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement', the company committed up to $380 million to secure exclusive access to automated cell therapy manufacturing capacity, underscoring the sector's strategic pivot toward high-throughput, closed-system production models.

Segmental Insights

Oncology stands as the fastest-growing segment in the Global Cell Therapy Market, driven by the surging global prevalence of hematologic malignancies and solid tumors. This rapid expansion is primarily fueled by the proven clinical efficacy of CAR-T cell therapies, which have demonstrated durable remission rates in patients unresponsive to traditional treatments. Furthermore, the segment benefits from a robust pipeline of investigational treatments and consistent product approvals from regulatory bodies such as the U.S. FDA and the EMA. These factors, combined with the increasing demand for precision medicine, continue to accelerate the adoption of cell-based oncological interventions.

Regional Insights

North America maintains a dominant position in the global cell therapy market, driven by extensive investments in research and development within the United States. This leadership is supported by a robust regulatory environment, where the U.S. Food and Drug Administration provides structured pathways for product approvals, enhancing commercial confidence. Additionally, the presence of major biotechnology firms and a strong network of academic institutions accelerates clinical trial progress. Favorable reimbursement policies and high healthcare expenditure further encourage the adoption of these therapies, ensuring sustained market expansion across the region.

Recent Developments

• In March 2025, AstraZeneca entered into a definitive agreement to acquire EsoBiotec, a biotechnology firm specializing in the development of in vivo cell therapies. The transaction, valued at up to $1 billion in total consideration, granted the pharmaceutical company access to a lentiviral vector platform capable of engineering immune cells directly within a patient's body. This technology aimed to circumvent the complex logistics associated with traditional ex vivo cell manufacturing by generating therapeutic cells in situ. The acquisition underscored a strategic industry shift toward developing scalable, "off-the-shelf" treatments that could be administered more rapidly than current autologous options.
• In December 2024, Kyowa Kirin and Cimeio Therapeutics announced a strategic research collaboration to develop novel treatments for severe autoimmune diseases and hematologic conditions. The partnership focused on utilizing a proprietary platform that shielded transplanted cells from antibody-based depletion, potentially allowing for more effective conditioning regimens. Under the terms of the agreement, Cimeio was eligible to receive payments totaling approximately US$300 million, including upfront and milestone figures. This alliance aimed to leverage combined expertise in antibody engineering and cell therapy to address unmet medical needs for patients requiring hematopoietic stem cell transplants.
• In August 2024, Adaptimmune Therapeutics received accelerated approval from regulatory authorities for its new engineered cell therapy targeting synovial sarcoma. This product became the first approved gene-modified T-cell therapy specifically indicated for a solid tumor malignancy, addressing a critical gap in the Global Cell Therapy Market. The treatment was designed for adult patients with advanced synovial sarcoma who carried a specific human leukocyte antigen type and whose tumors expressed the MAGE-A4 antigen. The approval relied on clinical data demonstrating durable response rates, offering a new therapeutic option for a patient population that historically faced limited effective treatment alternatives.
• In February 2024, the U.S. Food and Drug Administration granted accelerated approval to Iovance Biotherapeutics for a novel cellular medicine designed to treat adult patients with unresectable or metastatic melanoma. This regulatory milestone represented the first approval of a tumor-infiltrating lymphocyte therapy for a solid tumor indication, distinguishing it from earlier treatments that primarily targeted hematologic malignancies. The therapy was authorized for individuals who had previously progressed following treatment with a PD-1 blocking antibody and, if applicable, a BRAF inhibitor. This development marked a significant advancement in the commercial availability of autologous cell therapies within the global market.

Key Market Players

• Novartis AG
• Gilead Sciences, Inc.
• Bristol-Myers Squibb Company
• Johnson & Johnson Services, Inc
• JCR Pharmaceuticals Co., Ltd.
• Tego Science
• Atara Biotherapeutics
• Takeda Pharmaceutical Company Limited
• Bluebird Bio, Inc.
• Dendreon Corp.

By Therapy Type	By Therapeutic Area	By Region
Autologous Allogenic	Oncology Cardiovascular Diseases Musculoskeletal Disorders Dermatology	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Cell Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Cell Therapy Market, By Therapy Type:

• Autologous
• Allogenic

• Cell Therapy Market, By Therapeutic Area:

• Oncology
• Cardiovascular Diseases
• Musculoskeletal Disorders
• Dermatology

• Cell Therapy Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE